Nuvation Bio is a global oncology company developing therapies for difficult-to-treat cancers. Its lead commercial product, IBTROZI (taletrectinib), is an oral next-generation ROS1 inhibitor approved for advanced ROS1-positive non-small cell lung cancer. The broader pipeline includes a brain-penetrant IDH1 inhibitor and other targeted oncology programs, serving patients and specialists in precision cancer care.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 3.1 | — | -53.2 | — |
| Q2 2025 | 4.8 | — | -59 | — |
| Q3 2025 | 13.1 | — | -55.8 | — |
| Q4 2025 | 41.9 | — | -36.6 | — |
| Q1 2026 | 83.2 | 2,598.7% | 5.4 | — |
| Q2 2026 | 31.7 | 555.6% | -62.8 | — |
All markets — KeepWinning global stock screener
Other companies on NYSE: Sally Beauty Holdings, Inc. (SBH), Londian Wason New Energy Tech Inc. (FOIL), Century Communities, Inc. (CCS), Voyager Technologies, Inc. (VOYG), Permian Basin Royalty Trust (PBT), Savers Value Village, Inc. (SVV)